Neuren Pharmaceuticals Limited (OTCMKTS:NURPF – Get Free Report) saw a large growth in short interest in October. As of October 30th, there was short interest totaling 288,479 shares, a growth of 185.6% from the October 15th total of 101,010 shares. Based on an average trading volume of 1 shares, the days-to-cover ratio is presently 288,479.0 days.
Neuren Pharmaceuticals Stock Performance
OTCMKTS NURPF remained flat at C$13.76 on Friday. Neuren Pharmaceuticals has a one year low of C$7.70 and a one year high of C$17.25. The company’s fifty day moving average is C$14.51 and its 200-day moving average is C$11.66.
About Neuren Pharmaceuticals
Neuren Pharmaceuticals is an Australian biopharmaceutical company focused on developing treatments for serious neurodevelopmental disorders. Based in Melbourne, the company’s research centers on therapies intended to address conditions with limited treatment options. Its lead partnered medicine, trofinetide, is marketed in the United States by Acadia Pharmaceuticals as DAYBUE for Rett syndrome. Neuren developed the drug and licensed commercialization rights to Acadia. Neuren is also developing NNZ-2591, an investigational treatment being studied for several neurodevelopmental conditions, including Phelan-McDermid syndrome, Pitt-Hopkins syndrome, Angelman syndrome and Prader-Willi syndrome.
See Also
- Five stocks we like better than Neuren Pharmaceuticals
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Neuren Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuren Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
